In 2012 Menarini, initiated a partnership with the British Company Oxford BioTherapeutics, for the development of 5 innovative monoclonal antibodies for the treatment of cancer.
The antibodies have been designed to bind specifically the cancer cells. They can act either as "intelligent missiles" in order to deliver the toxins to destroy the cancer cells (ADC, Antibody Drug Conjugate, mechanism of action), or as death "mediator" of cancer cells through the activation of "killer" cells of the immune system (ADCC, Antibody-Dependent Cellular Toxicity, mechanism of action).
For two antibodies the development has already started:
- MEN1112, an ADCC in clinical phase I for acute myeloid leukemia
- MEN1309, an ADC in clinical phase I for B-Non-Hodgkin lymphoma and solid tumors like some subpopulations of breast cancer.
Press Release 29/10/2012